All cytology slide preparations must be evaluated on the premises of a laboratory certified in cytology. Written procedures must require Papanicolaou or modified Papanicolaou staining of gynecologic preparations, measures against cross-contamination between gynecologic and nongynecologic specimens during staining, and separate staining with filtered or changed stains for high-contamination nongynecologic specimens. The laboratory must establish and follow a written program to detect errors in cytologic examination and reporting that includes rescreening, before reporting, at least 10 percent of gynecologic cases interpreted as negative, randomly selected and including higher-risk patients, by a qualified technical supervisor, cytology general supervisor or experienced cytotechnologist; comparison of clinical information with cytology reports and of every HSIL, adenocarcinoma or other malignancy with available histopathology, with discrepancies explained; review of all negative gynecologic specimens from the previous five years for each patient with a current HSIL, adenocarcinoma or malignancy, with the physician notified and an amended report issued where a significant discrepancy affects current care; records of initial and rescreening results; an annual statistical evaluation of cases, specimen types, diagnoses, correlations, discrepancies and reclassified rescreens; and evaluation of each individual's case reviews against the laboratory's statistics. The technical supervisor must set a workload limit for each primary screener based on their rescreen and confirmation performance, reassessed at least every six months, and no individual may examine more than 100 slides in 24 hours or in less than an eight-hour workday (prorated for shorter days, half-slide counting for dispersed liquid-based nongynecologic preparations, and excluding the technical supervisor's tissue and previously examined slides), with records of slides examined and hours spent per individual and per 24 hours irrespective of site. A technical supervisor must confirm every gynecologic preparation showing reactive or reparative change or any listed squamous or glandular abnormality or malignancy, and review all nongynecologic preparations, with the report signed or electronically authorised to reflect that review; unsatisfactory preparations must be reported as such, reports must use narrative descriptive nomenclature, and corrected reports must state the basis for correction. Records and slides are retained per section 493.1105, slides loaned to PT programs with written acknowledgement, other loans documented, and all slides retrievable on request; automated and semi-automated screening devices are used per the manufacturer's instructions. All control procedures must be documented.
This control maps to 1 controls across 1 other frameworks. If you already hold one of them, the evidence you collected for it is the starting point here rather than new work.
Every mapping shown was judged rather than inferred from wording similarity, and the ones that failed review are published too. See the coverage reports and what was rejected.
The graph holds this control, the 1 it maps to, and the evidence behind each claim, over MCP and REST.